Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22,116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Concordance and Clinical Significance of Genomic Alterations in Progressive Tumor Tissue and Matched Circulating Tumor DNA in Aggressive-variant Prostate Cancer.
Wang R, Xu Q, Guo H, Yang G, Zhang J, Wang H, Xu T, Guo C, Yuan J, He Y, Zhang X, Fu H, Xu G, Zhao B, Xie J, Zhao T, Huang L, Zhang J, Peng B, Yao X, Yang B. Wang R, et al. Among authors: yang b, yang g. Cancer Res Commun. 2023 Nov 3;3(11):2221-2232. doi: 10.1158/2767-9764.CRC-23-0175. Cancer Res Commun. 2023. PMID: 37877742 Free PMC article.
Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer.
Wang H, Li N, Liu Q, Guo J, Pan Q, Cheng B, Xu J, Dong B, Yang G, Yang B, Wang X, Gu Y, Zhang G, Lian Y, Zhang W, Zhang M, Li T, Zang Y, Tan M, Li Q, Wang X, Yu Z, Jiang J, Huang H, Qin J. Wang H, et al. Among authors: yang b, yang g. Cancer Cell. 2023 Jul 10;41(7):1345-1362.e9. doi: 10.1016/j.ccell.2023.05.016. Epub 2023 Jun 22. Cancer Cell. 2023. PMID: 37352863 Free article.
Sustained complete response to first-line immunochemotherapy for highly aggressive TP53/MDM2-mutated upper tract urothelial carcinoma with ERBB2 mutations, luminal immune-infiltrated contexture, and non-mesenchymal state: a case report and literature review.
Xu T, Guo H, Xie J, He Y, Che J, Peng B, Yang B, Yao X. Xu T, et al. Among authors: yang b. Front Oncol. 2023 Jun 23;13:1119343. doi: 10.3389/fonc.2023.1119343. eCollection 2023. Front Oncol. 2023. PMID: 37427135 Free PMC article.
Re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phase 3 Trial. Lancet Oncol 2023;24:1094-108.
Ding L, Yang B, Yao X. Ding L, et al. Among authors: yang b. Eur Urol. 2024 Oct;86(4):e88-e89. doi: 10.1016/j.eururo.2023.10.024. Epub 2023 Nov 23. Eur Urol. 2024. PMID: 38000965 No abstract available.
Re: Cathrine Alvær Vinje, Maria Nyre Vigmostad, Svein R. Kjosavik, Henrik Grönberg, Bjørnar Gilje, Svein Skeie. Prostate Biopsies Can Be Omitted in Most Patients with a Positive Stockholm3 Test and Negative Prostate Magnetic Resonance Imaging. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.08.009.
Liu W, He Y, Yang B. Liu W, et al. Among authors: yang b. Eur Urol Focus. 2024 Mar;10(2):244-245. doi: 10.1016/j.euf.2023.11.016. Epub 2024 Jan 29. Eur Urol Focus. 2024. PMID: 38290858 No abstract available.
22,116 results
You have reached the last available page of results. Please see the User Guide for more information.